Amendment Eleven HHS-NIH-NIAID-BAA2020-1 .pdf

HHS-NIH-NIAID-BAA2020-1 Page 1 of 3 Amendment Eleven (11)

NIAID 2020 OMNIBUS BROAD AGENCY ANNOUNCEMENT

HHS-NIH-NIAID-BAA2020-1

AMENDMENT ELEVEN (11)

OFFICE OF ACQUISITIONS

National Institute of Allergy and Infectious Diseases (NIAID)

5601 Fishers Lane, Room 3D38, MSC 9821

Bethesda, MD 20892-9821

Solicitation Number: HHS-NIH-NIAID-BAA2020-1

Date of Solicitation Issuance: January 3, 2020

Date of Amendment

Eleven (11) Issuance: April 1, 2020

Number of Pages: 3

Proposal Due Dates:

The hour and date specified for receipt of offers for each Research Area remains unchanged:

RESEARCH

AREA

NIAID

DIVISION

TITLE RECEIPT DATE AND

TIME

001 DAIT Development of Radiation/Nuclear Medical Countermeasures (MCMs)

3:00 PM Eastern Time, 04/09/2020

003 DMID Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

3:00 PM Eastern Time, 04/09/2020

004 DMID Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases

3:00 PM Eastern Time, 04/09/2020

005 DMID Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases

3:00 PM Eastern Time, 04/09/2020

Points of Contact:

Division of Allergy, Immunology, and Transplantation (DAIT)

Research Area 001: Development of Radiation/Nuclear Medical Countermeasures (MCMs)

Liem Nguyen, Contracting Officer

Email: liem.nguyen@nih.gov

Phone: 240-669-5144 mailto:liem.nguyen@nih.gov

HHS-NIH-NIAID-BAA2020-1 Page 2 of 3

Division of Microbiology and Infectious Diseases (DMID)

Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging

Infectious Diseases

Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant

(AMR) Infections and Emerging Infectious Diseases

Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious

Diseases

Primary Contact:

Swee L. Teo, Contracting Officer

Email: teosl@niaid.nih.gov

Phone: 240-669-5173

Secondary Contact:

Brian Madgey, Contracting Officer

Email: brian.madgey@nih.gov

Phone: 240-627-3712

Offerors MUST acknowledge receipt of the amendment by Amendment number (s) and date of the amendment. Failure to receive your acknowledgment of this amendment may result in the rejection of your proposal.

Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.

PURPOSE OF SOLICITATION AMENDMENT

The purpose of Amendment Eleven is to:

I) Provide responses to questions received regarding the solicitation.

The responses are offered for information only and do not modify or become part of this solicitation.

Additional amendments may be provided as needed to address further questions and their related responses. All potential offerors are advised to refer back to all previous amendments for additional questions and clarification.

I) The Government’s responses to questions received regarding this solicitation are as follows:

GENERAL QUESTIONS

Question 1: Does NIH Late Application Policy Notice Number NOT-OD-20-091 apply to this BAA? Do I have until May 1, 2020 to submit a proposal?

Response: This BAA is a contract solicitation; it is not a grant. The above notice applies to grant applications. The proposal due dates for Research Areas 001, 003, 004, and 005 remain unchanged at mailto:teosl@niaid.nih.gov mailto:brian.madgey@nih.gov https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-091.html

HHS-NIH-NIAID-BAA2020-1 Page 3 of 3 the dates specified above.

Question 2: 1) Are patent prosecution expenses allowed?

2) What are the guidelines for fees, and can a university applicant request them?

3) Can proceeds from fees be used to pay for patent prosecution expenses ?

Responses: 1) In accordance with FAR 31.205-30, patent costs are allowable to the extent that they are incurred as requirements of a Government contract. This BAA does not require offerors to file patents;

therefore, patent costs are not allowed to be charged as direct cost to the contract.

2) In accordance with FAR 15.404-4, for experimental, developmental, or research work performed under a cost-plus-fixed fee contract, the fee shall not exceed 15 percent of the contract’s estimated cost, excluding fee. If it is the offeror’s standard business practice to consistently charge fee to federal awards, the offeror may propose fixed-fee.

3) A contractor has the discretion to expend its fee as they deem appropriate.

Question 3: Regarding Section 7. – Attachment No. 12 “Disclosure of Lobbying Activities, OMB Form SF- LLL form”, would the following statement in the Business Proposal be satisfactory for the proposal?

“We acknowledge the requirements and restrictions on funds being used for lobbying activities and assures that it is compliant is all respects to the law and HHS regulations.”

Response: If your institution has lobbying activities, you must complete, sign, and submit the Disclosure of Lobbying Activities. If your institution does not have lobbying activities, you can enter N/A in any field, such as item 10, sign, and submit the form.

PLEASE NOTE: In the questions/responses above, specific organizational names have been removed or replaced where possible as well as other minor adjustments.